[Evaluation of cellular and humoral immunity and individual sensitivity of T-lymphocytes to immunocorrectors in patients with diabetic retinopathy].
Zhaboiedov. H D HD; Bychkova. N H NH; Skrypnik. R L RL; Sydorova. M V MV
Key Findings
- Diabetic retinopathy patients showed T‑cell immune insufficiency
- Immune‑corrector drugs (splenin, thymalin, erbisol, thymogen) were given based on individual T‑cell sensitivity
- Personalized dosing was suggested to improve immune function
Practical Outcomes
- For biohackers, the work hints that thymalin might help when T‑cell function is low, but it’s specific to diabetic patients and requires lab testing to tailor doses, so it’s not a ready‑to‑use protocol for healthy individuals.
Summary
The study looked at people with diabetic eye disease and found their T‑cells weren’t working well, so the researchers gave them immune‑boosting drugs like thymalin and adjusted the dose based on each person’s response.
Abstract
Patients with diabetic retinopathy were studied for parameters characterizing cell-bound and humoral immunity. Revealed in the course of our study was T-cell immune insufficiency affecting processes of proliferation of T-lymphocytes and warranting adoption of immune correction therapy. Administration of immune correctors was individualized judging from sensitivity of T-lymphocytes to the drugs being employed (splenin, thymalin, erbisol, and thymogen).
Study Information
pubmed
2001